Short Interest in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Expands By 162.7%

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the recipient of a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 54,874 shares, a growth of 162.7% from the February 12th total of 20,891 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average daily volume of 174,825 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 174,825 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.0% of the shares of the company are sold short.

Chemomab Therapeutics Stock Performance

NASDAQ CMMB traded down $0.12 on Thursday, hitting $1.83. The stock had a trading volume of 40,665 shares, compared to its average volume of 83,346. The company has a market capitalization of $11.28 million, a price-to-earnings ratio of -0.62 and a beta of 0.41. Chemomab Therapeutics has a 52-week low of $1.35 and a 52-week high of $6.10. The firm has a 50-day moving average of $1.69 and a 200-day moving average of $2.36.

Analyst Upgrades and Downgrades

CMMB has been the topic of a number of research reports. Zacks Research cut shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Chemomab Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $25.00.

Institutional Trading of Chemomab Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC purchased a new stake in shares of Chemomab Therapeutics in the 4th quarter worth about $132,000. Kestra Private Wealth Services LLC bought a new position in shares of Chemomab Therapeutics during the fourth quarter valued at $85,000. Finally, XTX Topco Ltd purchased a new stake in shares of Chemomab Therapeutics during the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.